AstraZeneca Pharma India Ltd. — Board/Management Information 2023

May 30, 2023

==> picture [452 x 78] intentionally omitted <==

May 30, 2023

The Manager – Listing BSE Limited 1[st] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, 5[th] Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

With reference to the captioned Regulation, this is to inform that the Board of Directors at its Meeting held today i.e., May 30, 2023, considered and transacted inter alia the following business:

1. Noted the retirement of Mr. Rajesh Marwaha (DIN: 01458768) from the Office of Chief Financial Officer and Whole-time Director of the Company with effect from the closing of business hours on September 30, 2023. While taking note of the same, the Board has placed on record its sincere thanks and appreciation for his contribution during his tenure in the Company.

2. Based on the recommendation of the Nomination and Remuneration Committee and Audit Committee, the Board of Directors of the Company has approved the appointment of Mrs. Bhavana Agrawal as Chief Financial Officer of the Company with effect from October 1, 2023. Over the coming months, Mr. Rajesh Marwaha will support the transition of responsibility to Mrs. Bhavana Agrawal to ensure she gains swift understanding of our current stage of business and important stakeholder relationships. In the interim, she has been designated as Chief Financial Officer Designate and will subsequently be taking over the role and complete responsibilities of Chief Financial Officer upon the retirement of Mr. Rajesh Marwaha.

In this regard, please find the below details pursuant to Regulation 30 of Listing Regulations read with Clause 7 of the SEBI Circular dated September 09, 2015.

Sl.	Particulars	Information about the change	Information about the change
		Retirement of Mr. Rajesh Marwaha	Appointment of Mrs. Bhavana Agrawal
1.	Reason for change viz. appointment, resignation, removal, death, retirement or otherwise	Retirement of Mr. Rajesh Marwaha as Chief Financial Officer and Whole-time Director of the Company.	Appointment of Mrs. Bhavana Agrawal as Chief Financial Officer of the Company

==> picture [453 x 65] intentionally omitted <==

==> picture [452 x 78] intentionally omitted <==

2.	Date of appointment/cessation (as applicable) & term of appointment	September 30, 2023	October 1, 2023
3.	Brief profile (in case of appointment)	Not Applicable.	Mrs. Bhavana Agrawal comes with over two decades of finance experience and has worked across multiple geographies & businesses. She played various roles with GE and her last responsibility with the organisation was out of Dubai as a CFO ‐ Services business at GE Healthcare for Middle East, Africa & Russia where she led a team of senior finance professionals and held responsible for revenue, costs, cash, planning session & financial closing activities in 30+ countries. With her expertise around Commercial Finance, P&L Management & cost optimisation, financial planning /Analysis, Cash flow management, LEAN/process improvements, Accounting & Controls, she was a strategic finance partner for businesses with consistent performance in maximising revenue, margin & cash. She carries strong leadership with proven record in creating positive team culture & growth. Prior to her last role, she had performed multiple roles across finance domain between 2003 to 2015 in Dubai and India for GE. Mrs. Bhavana Agrawal is an All‐India rank holder as a Chartered Accountant. Earlier she completed her Bachelor of Business Studies in Delhi University. She is currently based in Dubai with her husband and 7 year old son and she would be relocating to India in July with her family. She enjoys traveling,

==> picture [453 x 65] intentionally omitted <==

==> picture [452 x 78] intentionally omitted <==

			hiking and reading in her free time.
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Not Applicable.	Neither related to any Director on the Board of Directors of the Company nor with the promoter of the Company.

Kindly take the above on your records.

Thanking you,

Yours faithfully, For AstraZeneca Pharma India Limited

MANAS Digitally signed by MANASA RAMA Date: 2023.05.30 A RAMA 17:14:47 +05'30'

Manasa. R Company Secretary

==> picture [453 x 65] intentionally omitted <==